Skip to main content

Table 2 Hospitalizations during the 6-month follow up period

From: Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Variable

Medicaid population

Commercial population

Lurasidone

Quetiapine

Lurasidone

Quetiapine

n = 122

n = 215

n = 116

n = 220

Episodes (N)a

125

226

118

223

All-cause hospitalizations

 Episodes with ≥1 admission, (N, %)

19

15

52

23

12

10

44*

20

 Length of stay (first admission), (Mean, SD)

5.4

4.3

6.7*

4.8

10.9

14.5

9.3

8.8

 Cost, among episodes with an admission (Mean, SD)

15,448

13,741

22,012*

23,581

16,265

16,377

27,368*

46,415

Mental health-related hospitalizations

 Episodes with ≥1 admission, (N, %)

18

14

48

21

10

9

42*

19

 Length of stay (first admission), (Mean, SD)

5.6

4.4

6.8*

5.0

12.5

15.5

9.8*

8.8

 Cost, among episodes with an admission (Mean, SD)

15,388

13,609

22,272*

24,385

16,512

17,903

27,398*

46,476

Schizophrenia-related hospitalizations

 Episodes with ≥1 admission, (N, %)

16

13

36

16

8

7

26

12

 Length of stay (first admission), (Mean, SD)

5.6

4.7

7.6*

5.0

14.4

17.0

13.8

21.7

 Cost, among episodes with an admission (Mean, SD)

14,193

12,876

21,579*

24,034

17,863

19,745

18,514

17,249

  1. aMonotherapy treatment episodes were defined as patients having more than one lurasidone or quetiapine prescription without overlapping other antipsychotics during the post-index period. As some patients had multiple episodes, the N value in this row refers to the number of episodes in the sample that were evaluated
  2. *(p < .05); Statistically significantly different from lurasidone cohort